Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

Nitric oxide (NO) is a short-lived, pleiotropic molecule that affects numerous critical functions
in the body. Presently, there are markedly conflicting findings in the literature regarding NO …

Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with
histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune …

RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS
being the most frequently mutated and MYC the most amplified. The cooperative interplay …

Introduction Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer
with no effective targeted therapy. Inducible nitric oxide synthase (iNOS) is associated with …

The inducible nitric oxide synthase (iNOS) is associated with more aggressive solid tumors,
including hepatocellular carcinoma (HCC). Notch signaling in cancer stem cells promotes …

KRAS mutations are one of the most frequent oncogenic mutations of all human cancers,
being more prevalent in pancreatic, colorectal, and lung cancers. Intensive efforts have been …

Inflammation is widely recognized as an inducer of cancer progression. The inflammation-
associated enzyme, inducible nitric oxide synthase (NOS2), has emerged as a candidate …

It is now largely admitted that a pro‐inflammatory environment may curtail anti‐tumor
immunity and favor cancer initiation and progression. The discovery that small non‐coding …

Inducible nitric oxide synthase (NOS2) produces high local concentrations of nitric oxide
(NO), and its expression is associated with inflammation, cellular stress signals, and cellular …